Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Pfizer's Phase 3 trial for the lung cancer drug Sigvotatug Vedotin failed to meet its primary endpoint for survival.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Pfizer announced topline Phase 3 results for sigvotatug vedotin in previously treated metastatic non-squamous non-small cell lung cancer. The experimental drug missed its main goal and failed to boost survival in the clinical trial.
Epilogue added 6d ago, after coverage quieted.
The brief
Pfizer has announced topline Phase 3 results for Sigvotatug Vedotin, an experimental drug originating from Seagen. The trial targeted patients with previously treated metastatic non-squamous non-small cell lung cancer, but the drug failed to boost survival and missed its main goal.
Coverage from Reuters, Bloomberg, and STAT News emphasizes the failure of the clinical trial, describing the drug as "closely watched." Yahoo Finance reports that PFE stock reacted to these mixed results. Future developments depend on Pfizer's interpretation of the topline data.
Coverage does not yet specify the company's next steps regarding the drug's development path.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 21d ago.
Quick answers
What drug was tested in the Phase 3 trial?
The drug tested was Sigvotatug Vedotin.
Which specific condition was the trial targeting?
The trial targeted previously treated metastatic non-squamous non-small cell lung cancer.
Where did the drug originate?
According to Yahoo Finance, the cancer drug originated from Seagen.
Coverage (5)
- Pfizer’s Lung Cancer Drug Trial Fails to Boost Survival Bloomberg.com · 21d ago
- Pfizer's experimental drug misses main goal of lung cancer trial Reuters · 21d ago
- PFE Stock Reacts To Mixed Topline Results For Seagen-Origin Cancer Drug Yahoo Finance · 21d ago
- Closely watched Pfizer lung cancer drug falls short in clinical trial statnews.com · 21d ago
- Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer Business Wire · 21d ago
Topics
Related trends
Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump
4 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Rare transplant gives Stage 4 lung cancer patients a second chance at life
Recent study findings indicate lung transplants may improve survival outcomes for patients diagnosed with stage 4 lung cancer.
Compass says depression drug has long-lasting benefits
Compass Pathways reports long-lasting benefits from its psilocybin depression treatment following a second Phase 3 trial.
NIKE, Inc. Announces Planned CFO Transition —
Nike has appointed former Pfizer executive David Denton as its new CFO during a period of strategic turnaround.
Definium’s LSD formula produces ‘best data ever seen’ in a pivotal depression trial, CEO says
Definium Therapeutics' LSD-based depression treatment shows promising results in a pivotal trial, driving stock surge